Form 4: Twist Bioscience COO Sells Shares for Tax Cover

Patrick John Finn, President and COO of Twist Bioscience, sold 2,240 shares of common stock at $30.875 per share to satisfy tax withholding obligations from restricted stock unit vesting.

Summary

• Patrick John Finn, President and COO of Twist Bioscience Corp (TWST), reported a transaction on October 23, 2025.
• Finn disposed of 2,240 shares of Twist Bioscience common stock.
• The shares were sold at a price of $30.875 per share.
• The total value of the shares sold was $69,160.
• The sale was a "sell to cover" transaction, mandated by the issuer's equity incentive plans to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
• This transaction does not represent a discretionary trade by Mr. Finn.
• Following the transaction, Mr. Finn beneficially owns 206,495 shares of common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary 'sell to cover' for tax obligations related to RSU vesting, which is a neutral event. It does not reflect positive or negative sentiment about the company's future performance.

Positives

• The transaction indicates the vesting of Restricted Stock Units (RSUs) for a key executive, which is a form of compensation.
• The sale was non-discretionary, solely to cover tax withholding obligations, not a reflection of management's sentiment about the company's future.

Negatives

• A reduction in direct beneficial ownership by a key executive, although non-discretionary, slightly decreases insider alignment.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
• These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes, which is common across all industries for executives receiving equity compensation. It does not provide information relevant to broader industry trends or competitive analysis.

Comparison to Industry Standards

• This filing reports a standard "sell to cover" transaction for tax obligations, a common practice for equity compensation across publicly traded companies. No specific comparable companies or projects are relevant here.

Stakeholder Impact

• Shareholders: Minimal impact, as it's a routine, non-discretionary transaction for tax purposes. It does not signal a change in management's confidence.

Key Dates

Keywords

Twist Bioscience, TWST, Patrick John Finn, Form 4, insider trading, stock sale, RSU vesting, tax withholding, sell to cover, executive compensation